From GlobeNewswire: 2025-05-07 07:00:00

Amarin Corporation plc reported financial results for the first quarter of 2025, showcasing multiple revenue streams worldwide from VASCEPA®/VAZKEPA®. Nasdaq listing compliance was regained after a 1-for-20 ADS ratio change. The company will host a conference call at 8:00 a.m. EDT. Revenue for Q1 2025 was $42.0 million, down 26% from the same period in 2024. Operating expenses were $41.9 million. Cash on hand was $281.8 million. The decrease in revenue was attributed to lower selling prices and volume due to U.S. generic competition. In the U.S., revenue was $35.7 million, in Europe $5.4 million, and in the Rest of World less than $0.1 million. The company’s financial results were not impacted by U.S. or ex-U.S. factors. Amarin reports no significant impact from U.S. or ex-U.S. tariffs. Cost of goods sold decreased to $16.9 million in Q1 2025, with gross margin at 59%. Selling expenses were $36.6 million, while R&D expenses were $5.3 million. Net loss was $15.7 million under GAAP, with an adjusted net loss of $9.4 million.

The company completed a 1-for-20 ADS ratio change to maintain Nasdaq listing. Amarin regained compliance with the minimum share price requirement. The revised total ADSs outstanding is 20,718,263. For more details on the ratio change, refer to the press release issued on April 9, 2025.

Amarin will host a conference call on May 7, 2025, at 8:00 a.m. ET to discuss Q1 2025 earnings. The call can be accessed on the company’s website or via phone. A replay will be available for two weeks. Amarin is a pharmaceutical company focused on cardiovascular disease management, with offices worldwide.

VASCEPA (icosapent ethyl) capsules, approved by the FDA, is a prescription treatment for high-risk patients with persistent cardiovascular risk. Since launch, VASCEPA has been prescribed over twenty-five million times. It is approved and sold in multiple countries worldwide, with marketing authorization granted under the brand name VAZKEPA in Europe. VASCEPA (icosapent ethyl) is approved and sold in multiple European countries. In the United States, it is indicated as an adjunct to statin therapy to reduce the risk of cardiovascular events in patients with elevated triglyceride levels. Important safety information includes contraindications and increased risks of atrial fibrillation and bleeding. Non-GAAP financial information is provided, and the press release contains forward-looking statements regarding Amarin’s achievements and outlook. Amarin communicates with investors and the public through its website and SEC filings. As of March 31, 2025, the company’s assets totaled $655,677, with $42,017 in total revenue and a net loss of $15,697 for the first quarter of 2025. Non-GAAP net loss was $9,355 for the same period.

A recent report on cardiovascular health in China highlights the importance of addressing cardiovascular diseases in the country. With cardiovascular diseases being a public health priority, initiatives and awareness are crucial. Vazkepa® (icosapent ethyl) is mentioned as a key product in managing cardiovascular health in China.



Read more at GlobeNewswire:: Amarin Reports First Quarter 2025 Financial Results